Skip to content
grad
Clinical Trials Portal

Clinical Trials Portal

Bon Secours Richmond Health System

  • Home
  • FAQs
Posted on August 16, 2017October 16, 2017 by Ian Johnson

SWOG S1418

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy

Read more about this trial →

← Back to available clinical trials

Post navigation

Previous PostPrevious NRG Oncology NRG-BR003
Next PostNext Alliance ALCHEMIST Trials A151216

Want to Know More?

Our Department participates in the National Cancer Institute Community Oncology Research  Program (NCORP). We are currently the top accruing site for treatment trials within our NCORP. We would not be able to hold this achievement without each of our patients and our hard work is a testament to them!

Check out these informational videos provided by the National Cancer Institute to learn more about Clinical Research.

APPOINTMENTS AVAILABLE

To inquire about participation in a clinical trial, please contact us by phone at (804) 893-8717 or by email at rvaoncologyresearch@bshsi.org

See our FAQs

logo

logo logo

Bon Secours International | Sisters of Bon Secours USA | Bon Secours Health System
This page is managed by the Bon Secours Richmond Health System in Richmond, VA.
© 2017 Bon Secours Health System, Inc.

  • Yelp
  • Facebook
  • Twitter
  • Instagram
  • Email
Proudly powered by WordPress